
|Videos|March 29, 2018
Treatment of NSCLC With Uncommon EGFR Mutations
Treatment of NSCLC With Uncommon EGFR Mutations
Advertisement
- A female patient, Chinese descent, aged 66, is referred from primary care with persistent cough, sputum with blood, shortness of breath and chest pain
- History
- Never smoked
- Recurrent bronchitis over past 5 years
- Has never been screened for lung cancer (by radiography or low-dose CT [LDCT])
- Hypertension controlled on HCTZ; no diabetes, renal impairment
- Family history
- Grew up in China, moved to US at age 29; married for 30 years
- Grew up in family with heavy smokers
- Husband is current smoker
- LDCT reveals multiple tumors in left lung with pleural metastases
- Biopsy reveals non-small cell lung cancer
- Molecular analysis:
- EGFRmutation: G719X
- Negative forALKrearrangement
- Wild-typeKRAS
- The patient was started on afatinib, 40 mg once daily
- After one month on therapy, she reported having rather severe diarrhea (5 times/day)
- Treatment was discontinued, then re-started treatment at 30 mg/day
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5






































